MedPath

Mifepristone

Generic Name
Mifepristone
Brand Names
Korlym, Mifegymiso
Drug Type
Small Molecule
Chemical Formula
C29H35NO2
CAS Number
84371-65-3
Unique Ingredient Identifier
320T6RNW1F
Background

Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).

Indication

For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.

Associated Conditions
Hyperglycemia
Associated Therapies
Medically induced abortion
Clinical Trials
Related News

The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy

Phase 4
Recruiting
Conditions
Abortion in First Trimester
Interventions
First Posted Date
2022-04-22
Last Posted Date
2025-01-22
Lead Sponsor
KK Women's and Children's Hospital
Target Recruit Count
144
Registration Number
NCT05341817
Locations
🇸🇬

KK Women's and Children's Hospital, Singapore, Singapore

Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

Phase 4
Recruiting
Conditions
Fetal Death
Fetal Demise From Miscarriage
Abortion, Second Trimester
Pregnancy Complications
PPROM
Rupture, Spontaneous
Fetal Demise
Fetal Death Before 22 Weeks With Retention of Dead Fetus
Pregnancy Loss
Interventions
First Posted Date
2022-04-11
Last Posted Date
2024-04-24
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
30
Registration Number
NCT05322252
Locations
🇺🇸

Barnes-Jewish Hospital, Saint Louis, Missouri, United States

Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages

Phase 3
Recruiting
Conditions
Miscarriage
Interventions
First Posted Date
2022-03-31
Last Posted Date
2023-09-06
Lead Sponsor
Calcutta National Medical College and Hospital
Target Recruit Count
120
Registration Number
NCT05304273
Locations
🇮🇳

Calcutta National Medical College and Hospital, Kolkata, West Bengal, India

RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Trauma

Phase 2
Completed
Conditions
Childhood Trauma
Major Depressive Disorder
Interventions
Drug: Placebo
First Posted Date
2022-02-01
Last Posted Date
2024-12-06
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
158
Registration Number
NCT05217758
Locations
🇳🇱

Amsterdam UMC, location VUmc, Amsterdam, Noord-Holland, Netherlands

Mifepristone Outpatient Labour Induction

Phase 3
Recruiting
Conditions
Labor, Induced
Interventions
Drug: Placebo
First Posted Date
2022-01-04
Last Posted Date
2023-09-06
Lead Sponsor
Chelsea and Westminster NHS Foundation Trust
Target Recruit Count
400
Registration Number
NCT05177510
Locations
🇬🇧

Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

🇬🇧

West Middlesex University Hospital, Isleworth, United Kingdom

🇬🇧

Chelsea and Westminster Hospital, London, United Kingdom

Long-term Use of Mifepristone in the Treatment of Adenomyosis

Early Phase 1
Conditions
Adenomyosis
Mifepristone
Interventions
First Posted Date
2021-12-09
Last Posted Date
2021-12-09
Lead Sponsor
Women's Hospital School Of Medicine Zhejiang University
Target Recruit Count
140
Registration Number
NCT05151016
Locations
🇨🇳

Women's Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China

Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks

Phase 4
Terminated
Conditions
Medical Abortion
Interventions
First Posted Date
2021-11-15
Last Posted Date
2023-07-25
Lead Sponsor
Gynuity Health Projects
Target Recruit Count
23
Registration Number
NCT05119439
Locations
🇺🇸

Planned Parenthood North Central States, Saint Paul, Minnesota, United States

🇺🇸

Philadelphia Women's Center, Philadelphia, Pennsylvania, United States

🇺🇸

University of Hawaii, Honolulu, Hawaii, United States

and more 1 locations

Mifepristone for Labor Induction

Phase 3
Completed
Conditions
Induced Vaginal Delivery
Interventions
First Posted Date
2021-10-28
Last Posted Date
2024-07-31
Lead Sponsor
Stanford University
Target Recruit Count
30
Registration Number
NCT05097326
Locations
🇺🇸

Lucile Packard Children's Hospital, Palo Alto, California, United States

Breast Cancer BRCA1 Carriers: a Pilot Study

Withdrawn
Conditions
TNBC - Triple-Negative Breast Cancer
BRCA1 Mutation
High-grade Serous Ovarian Cancer
Interventions
Procedure: Prophylactic mastectomy
First Posted Date
2021-09-30
Last Posted Date
2022-12-15
Lead Sponsor
Indiana University
Registration Number
NCT05062174
Locations
🇺🇸

IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana, United States

🇺🇸

Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States

Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal

Phase 4
Completed
Conditions
Abortion in Second Trimester
Interventions
First Posted Date
2021-09-16
Last Posted Date
2021-09-16
Lead Sponsor
Gynuity Health Projects
Target Recruit Count
120
Registration Number
NCT05046041
Locations
🇳🇵

Bharatpur Hospital, Bharatpur, Nepal

🇳🇵

Lumbini Provincial Hospital, Butwāl, Nepal

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy